Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2011Open Access

Factor VIII safety: plasma-derived versus recombinant products.

View Full Paper
Ask AI
Bookmark
Share

Authors

AGA. GringeriIstituto Superiore di Sanità

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

A. Gringeri (2011) studied this question.

synapsesocial.com/papers/6ab34ee1eb183d0301649c1bhttps://doi.org/10.2450/2011.0092-10
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Variant Creutzfeldt–Jakob disease: risk of transmission by blood and blood products2004 · 48 citations
  2. 2Back to the future: a recent history of haemophilia treatment2008 · 176 citations
  3. 3Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A2007 · 168 citations